Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine maintenance after perioperative FLOT for non-metastatic gastric cancer
IRCT20241228064191N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of capecitabine in gastric cancer (GC) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Tumor recurrence and Drug side effects. Started Mar 2025; status: completed.
02
Drugs
capecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on IRCT20241228064191N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241228064191N1.